ストックスクリーナーアプリを入手
19.87
0.60%
-0.12
アフターアワーズ：
19.87
前日終値:
$19.99
開ける：
$19.92
24時間の取引高:
453.49K
Relative Volume:
0.52
時価総額：
$1.49B
収益：
$384.03M
当期純損益:
$38.65M
株価収益率:
64.10
EPS:
0.31
ネットキャッシュフロー:
$196.35M
1週間 パフォーマンス:
+0.35%
1か月 パフォーマンス:
-5.29%
6か月 パフォーマンス:
+2.42%
1年 パフォーマンス:
+14.20%
1日の値動き範囲:
$19.79
$20.20
1週間の範囲:
$19.52
$20.20
52週間の値動き範囲:
$16.52
$22.76
Innoviva Inc Stock (INVA) Company Profile
INVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
19.87 | 1.49B | 384.03M | 38.65M | 196.35M | 0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | 開始されました | Goldman | Sell |
| 2025-08-11 | 開始されました | Oppenheimer | Outperform |
| 2025-07-14 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-20 | 開始されました | Goldman | Neutral |
| 2017-11-20 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Innoviva Inc (INVA) 最新ニュース
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA - MarketBeat
Avoiding Lag: Real-Time Signals in (INVA) Movement - Stock Traders Daily
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move? - AD HOC NEWS
Innoviva joins elite list of stocks with 95-plus composite rating - MSN
Pacer Advisors Inc. Sells 48,889 Shares of Innoviva, Inc. $INVA - Defense World
Scotiabank Initiates Coverage of Innoviva (INVA) with Sector Outperform Recommendation - MSN
Is Innoviva Inc stock in correction or buying zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - moha.gov.vn
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 65% Since Then - 富途牛牛
Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic - Sahm
Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Is Innoviva Inc a good long term investmentMarket Sentiment Report & Small Investment Portfolio - earlytimes.in
December 2026 Options Now Available For Innoviva (INVA) - Nasdaq
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug - Sahm
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating - Finviz
Technical Reactions to INVA Trends in Macro Strategies - Stock Traders Daily
Will Innoviva Inc. stock attract ESG investorsTrade Exit Report & Daily Profit Maximizing Trade Tips - Улправда
Will Innoviva Inc. (HVE) stock justify high valuation2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда
Will Innoviva Inc. (HVE) stock recover faster than industryJuly 2025 Short Interest & High Return Trade Guides - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Can Innoviva Inc. stock deliver surprise earnings beatMarket Growth Summary & Low Drawdown Momentum Ideas - Улправда
Aug Fed Impact: How Innoviva Inc. (HVE) stock compares with tech leadersInsider Selling & Short-Term High Return Ideas - Улправда
Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Weekly Recap & Daily Stock Trend Reports - Улправда
Is Innoviva Still Attractive Around $20 After Strong Multi Year Share Price Gains? - Yahoo Finance
How Innoviva Inc. stock responds to policy changesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - DonanımHaber
Why Innoviva Inc. stock is in analyst buy zoneWeekly Risk Summary & Stock Portfolio Risk Control - DonanımHaber
Is Innoviva Inc. stock positioned for digital transformationJuly 2025 Patterns & Long-Term Capital Growth Strategies - DonanımHaber
Can Innoviva Inc. stock deliver sustainable ROENew Guidance & Low Risk Entry Point Guides - DonanımHaber
Profit Recap: Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Catalysts & Weekly Stock Performance Updates - Улправда
Will Innoviva Inc. stock see PE expansion2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Innoviva, Inc. (NASDAQ:INVA) Receives $38.60 Average Target Price from Analysts - Defense World
HC Wainwright & Co. Maintains Innoviva (INVA) Buy Recommendation - Nasdaq
INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News - GuruFocus
Innoviva announces Lancet publication of 'positive' Zoliflodacin Phase 3 data - MSN
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - BioSpace
Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence - MSN
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm
US FDA approves Innoviva’s oral antibiotic for gonorrhea - WTAQ
US FDA approves Innoviva's oral antibiotic for gonorrhea - Reuters
Innoviva (NASDAQ: INVA) gets FDA approval for single-dose oral antibiotic NUZOLVENCE for gonorrhea - Stock Titan
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - BioSpace
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 - PharmiWeb.com
Trading the Move, Not the Narrative: (INVA) Edition - Stock Traders Daily
Innoviva, Inc. $INVA Shares Bought by Marshall Wace LLP - MarketBeat
State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA - MarketBeat
Edgestream Partners L.P. Invests $763,000 in Innoviva, Inc. $INVA - Defense World
Innoviva Inc (INVA) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):